Rifabutin Drug Asset Due Diligence Report 2026

This Rifabutin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Rifabutin can convert its Small molecule drug profile and RNAP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Rifabutin (query alias: rifabutin)
Modality / target	Small molecule drug; RNAP; RNAP inhibitors
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Pfizer Japan, Inc., BioVersys AG, Istituto Biochimico Italiano Giovanni Lorenzini SpA

The MCP disease footprint includes Mycobacterium Avium-Intracellulare Infection, Tuberculosis, Multidrug-Resistant, Mycobacterium Infections, Nontuberculous. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07514364	Phase 4	Recruiting	60	In the study period, we have screened 286 patients with kidney transplant and enrolled 50 participants who were KTR and had LTBI.
NCT07485010	Phase 2	Not yet recruiting	300	The primary outcome of the Intervention Program is microbiological clearance of Mycobacterium abscessus (MABS) with good tolerance of the interventions.
NCT07431307	Phase 2	Not yet recruiting	120	The incidence of treatment-related treatment emergent adverse events (TRTEAEs) in the Safety population, assessed through End of Study (EoS) visit in Part A and Part B.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers

Phase 1; n=110; evaluation: Positive. Reported fields: -; -; -

Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial

Phase 4; n=360; evaluation: Negative. Reported fields: H Pylori eradication rates = 90.0 % ( 82.8 - 94.5); H Pylori eradication rates = 75.8 % ( 67.0 - 83.0); H Pylori eradication rates = 90.8 % ( 83.8 - 95.1)

Bioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business Update

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Safety = generally safe and well tolerated ; Safety = generally safe and well tolerated

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Rifabutin addresses Mycobacterium Avium-Intracellulare Infection, Tuberculosis, Multidrug-Resistant, Mycobacterium Infections, Nontuberculous. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-03-31	BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health	Approved	Financial terms not disclosed
2022-10-25	OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support	Phase 1	Financial terms not disclosed
2022-10-25	OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Lyophilized formulations of rifabutin”. The milestone feed surfaced a patent-application signal described as “Intravenous rifabutin formulation and methods of making”. The milestone feed surfaced a patent-application signal described as “Rifabutin analogs for the treatment of disease”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO